Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 4 od 728  
Back povratak na rezultate
2021, vol. 149, br. 5-6, str. 295-300
Analiza faktora rizika za progresiju dijabetesne nefropatije kod bolesnika sa dijabetesom tipa 2
aUniverzitetska bolnica Foča, Republika Srpska, BiH + Univerzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH
bUniverzitet u Beogradu, Medicinski fakultet + Akademija medicinskih nauka, Srpsko lekarsko društvo, Beograd

e-adresakovacevicvmarijana@gmail.com
Sažetak
Uvod/Cilj: Cilj rada bio je da se ispita progresija dijabetesne nefropatije (DN) u trogodišnjem periodu i da se utvrde faktori rizika za progresiju DN. Metode: Studija je obuhvatila 45 bolesnika s dijabetesom tipa 2 i DN (26 muškaraca, starosti od 18 do 62 godine) koji su praćeni tri godine. Svim bolesnicima su urađeni fizikalni pregled i laboratorijske analize prilikom svakog pregleda. Laboratorijske analize su uključivale kompletnu krvnu sliku, serumsku glukozu, ureu, kreatinin, proteine, koncentraciju lipida, glikozilirani hemoglobin (HbA1c), koncentraciju proteina, albumina i kreatinina u urinu. Jačina glomerularne filtracije (JGF) izračunata je korišćenjem formule Modification of Diet in Renal Disease. Dužina bubrega i debljina parenhima izmereni su ultrazvukom. Rezultati: Koncentracije glukoze u serumu našte (12,0 ± 2,79 vs. 9,50 ± 2,22, p < 0,001) i HbA1c (7,99 ± 1,43 vs. 7,49 ± 1,29, p < 0,031) smanjivale su se tokom tri godine. Albuminurija se povećala (43,75 ± 10,83 vs. 144,44 ± 52,70 mg/l, p < 0,001) i JGF se značajno smanjila (63 vs. 58,3 ml/min/1,73 m2 ) tokom studije, dok je koncentracija lipida u serumu ostala nepromenjena. Srednja dužina bubrega i debljina parenhima smanjile su se tokom tri godine. Linearnom regresionom analizom utvrđeno je da su sistolni krvni pritisak, glikemija našte, HbA1c pozitivni, a dužina bubrega i debljina parenhima negativni prediktori povećanja proteinurije, dok je proteinurija izdvojena kao negativan, a koncentracija gvožđa i albumina u serumu kao pozitivni prediktor godišnje promene JGF. Zaključak: Visok krvni pritisak i visok HbA1c izdvojeni su kao značajni faktori rizika za povećanje proteinurije, koja je značajan prediktor smanjenja JGF kod bolesnika sa DN.
Reference
*** (2013) Summary of Recommendation Statements. Kidney Int Suppl, 3(1): 5-14
Aboelnasr, M.S., Shaltout, A.K., Alsheikh, M.R., Abdelhameed, A.H., Elrefaey, W. (2020) Diabetic kidney disease in patients newly diagnosed with type-2 diabetes mellitus: Incidence and associations. Saudi Journal of Kidney Diseases and Transplantation, 31(1): 191-9
American Diabetes Association (2018) 10 Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41(Suppl 1):S105-18
Antić, M., Jotić, A., Radović, M., Seferović, J.P., Lalić, N.M., Jovanović, D., Ležaić, V. (2009) Risk factors for the development of diabetic nephropathy. Srpski arhiv za celokupno lekarstvo, vol. 137, br. 1-2, str. 18-26
Coca, S.G., Ismail-Beigi, F., Haq, N., Krumholz, H.M., Parikh, C.R. (2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med, 172(10): 761-770
Đukanović, L. (2012) Prevencija dijabetesne nefropatije. Biomedicinska istraživanja, 3(2): 67-76
Fu, E.L., Evans, M., Clase, C.M., Tomlinson, L.A., van Diepen, M., Dekker, F.W., Carrero, J.J. (2021) Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. Journal of the American Society of Nephrology, 32(2): 424-435
Hsu, F.Y., Lin, F.J., Ou, H.T., Huang, S.H., Wang, C.C. (2017) Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney and Blood Pressure Research, 42(2): 358-368
Huang, R., Feng, Y., Wang, Y., Qin, X., Melgiri, N.D., Sun, Y., Li, X. (2017) Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. PLoS One, 12(1): e0168582-e0168582
International Diabetes Federation (2017) IDF Diabetes Atlas. Belgium, 8th edn., Available from: http://www.diabetesatlas.org; Accessed on January 23, 2019
Koszegi, S., Molnar, A., Lenart, L., Hodrea, J., Balogh, D.B., Lakat, T., Szkibinszkij, E., Hosszu, A., Sparding, N., Genovese, F., Wagner, L., Vannay, A., Szabo, A.J., Fekete, A. (2019) RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. Journal of Physiology, 597(1): 193-209
Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med, 130(6):461-70
Lezaić, V., Marinković, J., Milutinović, Z., Jovanović-Vasiljević, N., Vujičić, V., Pejović, B., Kalabić, S., Đukanović, L. (2018) Recording blood pressure and eGFR in primary care after the Belgrade screening study. Renal Failure, 40(1): 160-169
Ministarstvo Zdravlja I.Socijalne Zaštite Republike Srpske (2014) Klinički vodič 'Diabetes mellitus'. Banja Luka
Patel, D.M., Bose, M., Cooper, M.E. (2020) Glucose and Blood Pressure-Dependent Pathways: The Progression of Diabetic Kidney Disease. International Journal of Molecular Sciences, 21(6): 2218-2218
Patel, V., Shastri, M., Gaur, N., Jinwala, P., Kadam, A.Y. (2018) A study in prevalence of diabetic nephropathy in recently detected cases of type 2 diabetes mellitus as evidenced by altered creatinine clearance, urinary albumin and serum creatinine, with special emphasis on hypertension, hypercholesterolemia and o. International Journal of Advances in Medicine, 5(2): 351-5
Ren, W., Zhao, C., Wang, Y., Fang, Y., Huang, Z., Chen, W., Wang, L., Hu, W., Wang, K., Ni, L. (2019) Ramipril can alleviate the accumulation of renal mesangial matrix in rats with diabetic nephropathy by inhibiting insulin-like growth factor-1. Acta Cirurgica Brasileira, 34(1): 20190010000007-20190010000007
Resić, H., Mešić, E. (2015) Nadomještanje bubrežne funkcije u Bosni I Hercegiovini 2001-2014. Sarajevo: Institut za naučno-istraživački rad i razvoj UKCS, str. 42-50
Reutens, A.T., Atkins, R.C. (2011) Epidemiology of Diabetic Nephropathy. Contributions to Nephrology, 170: 1-7
Saran, R., Robinson, B., Abbott, K.C., Agodoa, L.Y.C., Bhave, N., Bragg-Gresham, J., et al. (2018) US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis, 71(3 Suppl 1): A7. Erratum in: Am J Kidney Dis. 2018, 71(4): 501
Sethi, S.K., Kumar, R. (2021) Prevalence of nephropathy and its parameters in patients with diabetes mellitus: A prospective study in a Central Indian Population. J Adv Med Dent Scie Res, 9(1):35-9
Shichiń, M., Kishikawa, H., Ohkubo, Y., Wake, N. (2000) Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23(Suppl 2): B21-9
Testa, R., Bonfigli, A.R., Prattichizzo, F., La, S.L., de Nigris, V., Ceriello, A. (2017) The 'Metabolic Memory' Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients, 9(5): 437-437
Toplak, H., Hoppichler, F., Wascher, T.C., Schindler, K., Ludvik, B. (2016) Adipositas und Typ 2 Diabetes / Obesity and type 2 diabetes. Wien Klin Wochen schr, 28(2):196-200
Trikkalinou, A., Papazafiropoulou, A.K., Melidonis, A. (2017) Type 2 diabetes and quality of life. World Journal of Diabetes, 8(4): 120-9
Yamazaki, T., Mimura, I., Tanaka, T., Nangaku, M. (2021) Treatment of Diabetic Kidney Disease: Current and Future. Diabetes & Metabolism Journal, 45(1): 11-26
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH200809013K
primljen: 09.08.2020.
revidiran: 20.02.2021.
prihvaćen: 10.03.2021.
objavljen onlajn: 16.03.2021.
objavljen u SCIndeksu: 10.07.2021.